股票代码：688505 股票简称：复旦张江 编号：临 2025-014 上海复旦张江生物医药股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好、有保本约定的投资产品（包括但不限 于购买保本型理财产品、结构性存款、大额存单、定期存款、通知存款等）。 投资金额及期限：上海复旦张江生物医药股份有限公司（以下简称"公 司"或"本公司"）使用额度不超过人民币18,000万元（包含本数）的暂时闲置 募集资金进行现金管理，使用期限自2025年6月20日起12个月之内有效。在前述 额度及使用期限范围内，资金可以循环滚动使用。 已履行的审议程序：公司于2025年4月28日召开第八届董事会第十次会议、 第八届监事会第九次会议，分别审议通过了《关于使用暂时闲置募集资金进行现 金管理的议案》，公司保荐机构国泰海通证券股份有限公司（以下简称"保荐机 构"）对上述事项出具了明确的核查意见。 特别风险提示：本次现金管理方式是安全性高、流动性好、保本型的理 ...

上海复旦张江生物医药股份有限公司 2024 年度股东周年大会 会议资料 二〇二五年六月 | 目录 | | --- | | 会议须知 | | | 1 | | --- | --- | --- | --- | | 会议议程 | 3 | | | | 会议议案 | 5 | | | | 议案 1：《关于 | 5 2024 | 年度董事会（工作）报告的议案》 | | | 议案 2：《关于 | 2024 11 | 年度监事会（工作）报告的议案》 | | | 议案 | 股年度报告及摘要；及 股经 A H | 3：《关于本公司截至二零二四年十二月三十一日止 | | | | 审计的财务报表及核数师报告的议案》 14 | | | | 议案 4：《关于 | 15 2024 | 年度财务决算报告的议案》 | | | 议案 5：《关于 | 2024 17 | 年度利润分配预案的议案》 | | | 议案 6：《关于续聘 | 19 | 年度境内外会计师事务所的议案》 2025 | | | 议案 7：《关于公司 | 2025 年度薪酬方案的议案》 20 | 2024 年度董事、监事薪酬执行情况及 | | | 议案 | 8：《关于提请股东大会授权 ...

证券代码：688505 证券简称：复旦张江 公告编号：临 2025-015 上海复旦张江生物医药股份有限公司 关于召开2024年度股东周年大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年度股东周年大会 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 26 日 至2025 年 6 月 26 日 股东大会召开日期：2025年6月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 26 日 14 点 00 分 召开地点：上海市浦东新区碧波路 699 号上海博雅酒店一楼会议室 （五） 网络投票的系统、起止日期和投票时间。 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 ...

股票代码：688505 股票简称：复旦张江 编号：临2025-013 上海复旦张江生物医药股份有限公司 第八届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 经与会监事审议，做出如下决议： （一）审议通过《关于公司 2025 年第一季度报告的议案》 监事会认为：《公司 2025 年第一季度报告》的编制及审议程序均符合法律、 法规、规范性文件和《公司章程》的要求，格式和内容符合上海证券交易所的各 项规定，内容真实、准确、完整地反映出公司本报告期经营管理和财务状况，不 存在任何虚假记载、误导性陈述或者重大遗漏。在作出本决议之前，未发现参与 2025 年第一季度报告编制和审议的人员存在违反相关制度和规定的行为。因此， 同意《公司 2025 年第一季度报告》相关内容。 表决情况：3 票同意，0 票反对，0 票弃权。 （二）审议通过《关于使用暂时闲置募集资金进行现金管理的议案》 上海复旦张江生物医药股份有限公司（以下简称"公司"或"本公司"）第八届 监事会第九次会议于 2025 年 ...

上海复旦张江生物医药股份有限公司2025 年第一季度报告 公司 H 股代码：01349 证券简称：复旦张江 上海复旦张江生物医药股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人赵大君、主管会计工作负责人薛燕及会计机构负责人（会计主管人员）章雯保证季度 报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 年同期增减变 | | | | | 动幅度(%) | | 营业收入 | 179,906,064 | 147,647,109 | 21.85 | | 归属于上市公司股东的净利润 | 2,665,11 ...

Financial Performance - Total revenue for the year ended December 31, 2024, was RMB 709,405,000, a decrease of 16.6% compared to RMB 850,733,000 in 2023[5] - Profit before tax for 2024 was RMB 5,458,000, down 94.4% from RMB 97,528,000 in 2023[5] - Net profit attributable to shareholders for 2024 was RMB 39,734,000, a decline of 63.4% from RMB 108,627,000 in 2023[5] - The company's revenue decreased by 17% year-on-year during the reporting period[34] - The company's revenue for the fiscal year 2024 was approximately RMB 709,405 thousand, a decrease of 17% compared to RMB 850,733 thousand in 2023, primarily from core business operations[55] - Revenue from the sale of medical and diagnostic products in 2024 was RMB 709,378 thousand, accounting for 99.9963% of core business revenue, also down 17% from RMB 850,564 thousand in 2023[57] - The net profit for 2024 was approximately RMB 39,434 thousand, a decline of about 64% from RMB 108,450 thousand in 2023, with a net profit margin of 6% compared to 13% in the previous year[67] - Sales revenue from Aira® decreased by 13% compared to the same period last year[35] - Sales revenue from Libod® declined by 28% year-on-year[36] - Sales revenue from Fumida® dropped by 4% compared to the previous year[37] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 2,586,503,000, a decrease of 10.1% from RMB 2,876,688,000 in 2023[6] - Total liabilities for 2024 were RMB 281,226,000, down 45.4% from RMB 518,124,000 in 2023[6] - The company has a cash and cash equivalents balance of approximately RMB 1,056,286 thousand as of December 31, 2024, down from RMB 1,195,896 thousand as of December 31, 2023[78] - The company has no outstanding bank financing as of December 31, 2024, indicating a debt-free status[75] Research and Development - The company plans to strategically focus on the development and industrialization of photodynamic therapy technology, leveraging its competitive advantages in this area[11] - The company aims to accelerate the research and industrialization of antibody-drug conjugates (ADCs), despite the competitive landscape in this field[11] - The company has established multiple technology platforms, including gene engineering and nanotechnology, to support ongoing drug development projects[10] - The company emphasizes a balanced approach between innovation and industrialization, as well as research and marketing[12] - Research and development expenses increased by 29% to RMB 314,162 thousand in 2024, up from RMB 243,763 thousand in 2023, reflecting a commitment to ongoing R&D projects[60] - The company is focusing on research and development in its advantageous fields, including photodynamic technology and nanotechnology[43] - The company is committed to continuous innovation and the development of new projects to provide valuable treatment options for patients[43] - The company has made significant progress in R&D, including the initiation of clinical trials for multiple drug candidates targeting various cancers and diseases[51] Clinical Trials and Product Development - The current pipeline includes photodynamic therapy (PDT) and photodynamic diagnosis (PDD), targeting conditions such as cervical precancerous lesions and breast cancer[14] - The photodynamic treatment for severe acne using aminolevulinic acid (ALA) has completed Phase II clinical trials, with results presented at the European Society for Dermatological Research meeting[20] - The clinical study for ALA in treating cervical precancerous lesions has completed Phase II trials and will soon enter Phase III trials, aiming for new indication registration[19] - The company is developing intraoperative molecular imaging (IMI) technology for real-time tumor visualization during surgeries, particularly for gliomas and bladder cancer[16] - The clinical trial for the use of aminolevulinic acid hydrochloride granules in non-muscle invasive bladder cancer (NMIBC) surgery has received approval, with the first subject enrolled during the reporting period[22] - The clinical trial for the use of aminolevulinic acid hydrochloride granules in breast-conserving surgery for breast cancer has also received approval, addressing a significant clinical need in real-time tumor margin assessment[24] - The global first photodynamic drug for treating infantile hemangioma, Heimofen, has completed the enrollment of the first subject in its Phase II clinical trial in the U.S.[25] - The first antibody-drug conjugate (ADC) developed by the company, targeting CD30, has had its Phase I clinical trial results presented at the American Society of Hematology meeting, although its advancement has been temporarily paused due to strategic considerations[27] - The second ADC targeting Trop2 for triple-negative breast cancer and other tumors has completed the enrollment of the first subject in its Phase III clinical trial for triple-negative breast cancer[28] Market and Industry Trends - The global pharmaceutical market is expected to exceed USD 1.1 trillion in 2024, with a projected compound annual growth rate of 3-6% until 2026[49] - By 2025, the Chinese pharmaceutical market is estimated to reach RMB 2.1 trillion, with the biopharmaceutical market expected to account for 48% of this[49] - The global biopharmaceutical industry is undergoing profound changes driven by new technologies, with a shift towards patent cooperation and mergers and acquisitions[50] - The Chinese pharmaceutical industry is a strategic emerging industry, with a focus on accelerating the development of innovative drugs and biomanufacturing as new growth engines[131] - The market for broad skin disease treatment and care in China grew from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a compound annual growth rate of 11.95%[132] - The incidence of skin diseases is increasing, with a significant rise in the number of patients and treatment visits, indicating a growing market demand[132] Corporate Governance and Financial Policies - The company has established a robust corporate governance structure to enhance transparency and accountability, thereby protecting shareholder interests and boosting investor confidence[190] - The company has implemented a stable and proactive profit distribution policy since 2015, prioritizing cash dividends when profits are available[170] - The company plans to maintain a cash dividend ratio of no less than 10% of the distributable profits in the first three years post-IPO[170] - The company has a conservative financial policy to ensure that its assets do not bear unnecessary risks, with no outstanding bank loans as of the reporting date[79] Employee and Management Information - The employee cost for the year 2024, including director remuneration, was RMB 232,115 thousand, compared to RMB 238,468 thousand in 2023[82] - The company has not provided employee dormitories during the year, and details regarding housing provident funds are included in the financial statements[188] - The company has purchased liability and indemnity insurance for directors and senior management, covering responsibilities related to both H-shares and A-shares listings[199]

Financial Performance - The company's operating revenue for the first quarter was RMB 179,906,064, representing a year-on-year increase of 21.85% compared to RMB 147,647,109 in the same period last year[5]. - Net profit attributable to shareholders was RMB 2,665,114, reflecting a growth of 13.53% from RMB 2,347,396 in the previous year[5]. - Net profit for Q1 2025 was RMB 2,581,403, compared to RMB 2,259,878 in Q1 2024, showing a growth of 14.2%[20]. Cash Flow - The net cash flow from operating activities decreased significantly by 84.34%, amounting to RMB 6,880,311, down from RMB 43,938,388 in the same period last year[5][10]. - For the first quarter of 2025, the net cash flow from operating activities was RMB 6,880,311, a decrease of 84.7% compared to RMB 43,938,388 in the first quarter of 2024[21]. - Total cash inflow from operating activities was RMB 238,939,006, down 2.9% from RMB 244,729,122 in the same period last year[21]. - Cash outflow from operating activities increased to RMB 232,058,695, up 15.5% from RMB 200,790,734 in the first quarter of 2024[21]. - The net cash flow from investing activities was -RMB 283,810,018, compared to -RMB 3,807,572 in the first quarter of 2024, indicating a significant increase in cash outflow[21]. - Cash inflow from investing activities totaled RMB 591,051,753, a decrease of 35.6% from RMB 919,724,441 in the previous year[21]. - Cash outflow from investing activities was RMB 874,861,771, down 5.3% from RMB 923,532,013 in the first quarter of 2024[21]. - The net cash flow from financing activities was -RMB 2,005,026, compared to -RMB 2,669,076 in the first quarter of 2024[21]. - The ending cash and cash equivalents balance was RMB 777,319,430, a decrease of 37.0% from RMB 1,233,394,449 at the end of the first quarter of 2024[21]. - The company received RMB 8,367,074 in other cash related to operating activities, an increase of 121.5% from RMB 3,769,626 in the first quarter of 2024[21]. - The company reported a cash flow impact from foreign exchange fluctuations of -RMB 31,466, compared to a positive impact of RMB 36,712 in the first quarter of 2024[21]. Research and Development - Research and development expenses totaled RMB 84,068,447, which is an increase of 31.00% compared to RMB 64,173,693 from the previous year[5][10]. - The ratio of R&D investment to operating revenue increased to 46.73%, up by 3.27 percentage points from 43.46% in the previous year[8]. - R&D expenses rose to RMB 84,068,447 in Q1 2025, compared to RMB 63,616,910 in Q1 2024, indicating a focus on innovation and product development[20]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,531,022,514, a decrease of 2.14% from RMB 2,586,502,623 at the end of the previous year[8]. - The total assets as of March 31, 2025, amounted to RMB 2,531,022,514, a decrease from RMB 2,586,502,623 as of December 31, 2024[19]. - Total liabilities decreased to RMB 223,197,709 as of March 31, 2025, down from RMB 281,225,518 at the end of 2024[19]. - The total equity attributable to shareholders reached RMB 2,307,198,823 as of March 31, 2025, slightly up from RMB 2,304,567,412 at the end of 2024[19]. Shareholder Information - The company reported a total of 19,246 common shareholders at the end of the reporting period[13]. - The top ten shareholders held a combined total of 1,339,000,000 shares, representing significant ownership concentration[14]. Government Subsidies and Market Strategy - The company received government subsidies amounting to RMB 4,538,759, which are closely related to its normal business operations[7]. - The company plans to adjust its sales strategies and pricing for the drug Libao Duo® in response to changes in the national drug procurement landscape starting April 2025[17]. - The company is focusing on optimizing its marketing network and customer base in light of provincial medical insurance policies[17]. Credit Impairment - The company reported a significant increase in credit impairment losses, amounting to RMB 14,720,951 in Q1 2025, compared to a reversal of RMB 5,559,028 in Q1 2024[20].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 4 月 28 日（周一）至 5 月 7 日（周三）16:00 前登录上证 路演中心网站首页，点击"提问预征集"栏目或通过公司邮箱 ir@fd-zj.com 进行 提问。公司将在文字互动环节对投资者普遍关注的问题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）已于 2025 年 3 月 28 日于上海证券交易所网站（www.sse.com.cn）披露了公司 2024 年年度报告， 为便于广大投资者全面深入地了解公司 2024 年度经营成果、财务状况，公司计 划于 2025 年 5 月 8 日（周四）15:00-17:00 参加 2024 年度科创板创新药行业集 体业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 股票代码：688505 股票简称：复旦张江 公告编号：临 2025-012 上海复旦张江生物医药股份有限公司关于参加 2024 年度科创板创新药行业集体业绩说明会的公告 本次业绩说明会以线上文字互动形式召 ...

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 709,405,000, a decrease of 16.6% compared to RMB 850,733,000 in 2023[3] - Profit before tax for 2024 was RMB 5,458,000, down 94.4% from RMB 97,528,000 in 2023[3] - Net profit attributable to shareholders for 2024 was RMB 39,734,000, a decline of 63.4% from RMB 108,627,000 in 2023[3] - The company reported a basic and diluted earnings per share of RMB 0.0383 for 2024, down 63.5% from RMB 0.1051 in 2023[3] - The company’s total comprehensive income for 2024 was RMB 39,745,000, compared to RMB 107,793,000 in 2023, a decrease of 63.1%[3] - Net profit for 2024 was RMB 39,434,072, down 63.6% from RMB 108,449,858 in 2023[9] - The company reported a net profit attributable to shareholders of RMB 39,733,896 for 2024, down from RMB 108,627,368 in 2023, representing a decrease of approximately 63.4%[176] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 2,586,503,000, a decrease of 10.1% from RMB 2,876,688,000 in 2023[4] - Total liabilities decreased to RMB 281,226,000 in 2024 from RMB 518,124,000 in 2023, representing a reduction of 45.4%[6] - Total liabilities decreased significantly to RMB 217,064,267 in 2024, down 52.3% from RMB 450,634,658 in 2023[8] - Total equity decreased to RMB 2,273,482,301 in 2024, a decline of 4.4% from RMB 2,379,229,295 in 2023[8] - The company’s current liabilities totaled RMB 202,636,602 in 2024, a decrease of 53.8% from RMB 439,267,111 in 2023[8] Cash Flow - Consolidated operating cash flow for 2024 was a net outflow of RMB 16,512,634, compared to a net inflow of RMB 71,015,450 in 2023, representing a significant decline[12] - The ending cash balance for 2024 was RMB 1,056,285,629, down from RMB 1,195,895,997 in 2023, representing a decrease of about 11.7%[12] - Operating cash inflow for the company was RMB 686,316,914 in 2024, a decline from RMB 787,256,011 in 2023, indicating a decrease of approximately 12.8%[13] - The company experienced a net cash outflow from operating activities of RMB 48,970,056 in 2024, compared to a net inflow of RMB 10,422,159 in 2023[13] - The company’s net cash decrease for 2024 was RMB 123,954,045, compared to RMB 120,474,705 in 2023, indicating a slight increase in cash outflow[13] Research and Development - Research and development expenses increased to RMB 314,162,142 in 2024, up 29% from RMB 243,762,975 in 2023[9] - Total R&D expenditure for 2024 amounted to RMB 314,162,142, an increase from RMB 244,700,356 in 2023, representing a growth of approximately 28.3%[151] - Outsourced R&D costs in 2024 were RMB 122,046,365, compared to RMB 94,265,372 in 2023, reflecting a year-over-year increase of about 29.5%[151] Inventory and Impairment - The company’s inventory increased to RMB 47,265,443 in 2024 from RMB 43,651,360 in 2023, an increase of 3.5%[5] - The inventory value as of December 31, 2024, was RMB 47,837,018, with a provision for inventory impairment of RMB 571,575, compared to RMB 44,368,610 and RMB 717,250 respectively in 2023[126] - The company reported a significant reduction in inventory impairment provisions for finished goods, decreasing from RMB 662,517 in 2023 to RMB 111,476 in 2024[127] - The inventory write-down provision decreased to RMB 571,575 in 2024 from RMB 717,250 in 2023, showing a reduction of about 20.3%[158] Dividends and Retained Earnings - The company distributed dividends amounting to RMB 93,291,489 to shareholders during 2024, which contributed to the decrease in retained earnings[15] - The company declared a cash dividend of RMB 0.07 per share for the 2023 fiscal year, totaling RMB 72,560,047 based on 1,036,572,100 shares issued[176] - The company plans to distribute a cash dividend of RMB 0.02 per share for the first half of 2024, amounting to RMB 20,731,442[176] Government Grants and Subsidies - Government grants are recognized when conditions are met, measured at the amount received or receivable, and can be related to assets or income[77] - Government subsidies received amounted to RMB 19,397,448 in 2024, a decrease from RMB 25,580,068 in 2023[186] - The company received government subsidies amounting to CNY 29,144,056 in 2024, an increase from CNY 23,197,893 in 2023[194] Financial Instruments and Investments - The company recognizes expected credit losses based on historical experience and current conditions, applying a three-stage model for credit risk assessment[39] - The company reported a loss of RMB 7,974,882 from its investment in Shanghai Handoo Pharmaceutical Technology Co., Ltd. for the year 2024[141] - The total long-term equity investments as of December 31, 2024, were RMB 257,482,937, down from RMB 287,518,193 in 2023, indicating a decrease of 10.4%[133] Accounting Policies and Compliance - The company’s financial statements are prepared in accordance with the Chinese accounting standards, ensuring compliance and transparency in financial reporting[22] - The financial statements for the year 2024 are prepared based on the going concern assumption, reflecting the consolidated and company financial position as of December 31, 2024[23] - The company has adopted the new accounting standards (Interpretation No. 17 and No. 18) issued in 2023 and 2024, which did not have a significant impact on its financial statements[93]

Financial Performance - Revenue for the first half of 2024 was RMB 408.12 million, a decrease of 21.94% compared to RMB 522.83 million in the same period last year[6]. - Net profit attributable to shareholders for the first half of 2024 was RMB 70.47 million, representing a 2.97% increase from RMB 68.44 million in the previous year[6]. - The company's operating income for the reporting period was 408,123,863 yuan, a decrease of 21.94% from 522,827,706 yuan in the same period last year[62]. - The company reported a net profit of RMB 70,473,064 for the six months ended June 30, 2024, compared to a net profit of RMB 68,437,509 for the same period in 2023, reflecting a growth of approximately 2.99%[162]. - The sales revenue from the product Aira® decreased by 9.37% compared to the same period last year[57]. - The sales revenue from the product Liboduo® declined by 45.83% year-on-year, significantly impacting the overall revenue of the group[57]. - The sales revenue from the product 复美达® increased by 36.17% compared to the previous year[58]. Research and Development - The company's R&D expenditure accounted for 38.06% of revenue, an increase of 15.38 percentage points from 22.68% in the same period last year[7]. - The total R&D investment for the period was approximately CNY 155.33 million, representing a 30.98% increase compared to the previous period[28]. - The company filed for 17 new patents during the reporting period, with 3 patents granted, bringing the total granted patents to 96[27]. - The company has ongoing clinical trials for multiple innovative drugs, including a new compound for treating bladder cancer and a targeted therapy for triple-negative breast cancer, both at advanced stages of research[34]. - The company is committed to developing drugs that address unmet clinical needs, ensuring a balance between innovative and generic drug development[33]. - The company has made significant progress in its R&D pipeline, with several projects nearing completion of clinical trials[34]. - The company has established a nanotechnology platform aimed at enhancing drug solubility and bioavailability, with its liposomal formulation, Liboduo®, launched in August 2009[24]. Market Position and Strategy - The company operates in the biopharmaceutical sector, focusing on innovative research, development, manufacturing, and marketing[11]. - The company aims to maximize economic benefits by developing differentiated products that meet clinical needs while maintaining competitive advantages[20]. - The company is strategically focusing on expanding its market presence and enhancing its product offerings in response to competitive pressures and market dynamics[57]. - The company is exploring new sales models to address common challenges in the current marketing environment and improve patient access to treatments[36]. - The company is adopting a cautious and conservative approach to R&D expense capitalization, considering the risks and challenges associated with innovative drug development[57]. Financial Health - The total assets as of June 30, 2024, were RMB 2,848.70 million, a decrease of 0.97% from RMB 2,876.69 million at the end of the previous year[6]. - Total liabilities as of June 30, 2024, were RMB 491.27 million, down from RMB 518.12 million at the end of the previous year[6]. - The company has a conservative financial policy, focusing on centralized management of funds and regular assessments of asset liquidity[68]. - The company has no significant investment or capital expenditure plans as of June 30, 2024[68]. - The company has a long-term equity investment net value of RMB 279,219,000, with a significant stake of RMB 226,503,000 in Handu Pharmaceutical, representing 7.95% of total assets[73]. Clinical Trials and Innovations - The company received approval for Phase II clinical trials for its hydrochloride amine pentanoic acid granules for breast cancer surgery visualization in January 2024[26]. - The company is conducting a Phase I clinical study for its anti-Trop2 antibody conjugate SN38 for advanced solid tumors, with results published on ASCO's website[26]. - The company has developed a range of products including cytokines, fusion proteins, monoclonal antibodies, and antibody-drug conjugates (ADCs) based on its gene engineering technology platform, which has become feasible for industrialization as the company expands[21]. - The company is advancing clinical trials for ALA granules in breast-conserving surgery for breast cancer[46]. - The company is also advancing intraoperative molecular imaging (IMI) technology for real-time tumor visualization during surgeries, which could improve surgical outcomes[42]. Corporate Governance and Compliance - The audit committee reviewed the financial statements for the six months ending June 30, 2024, and confirmed compliance with applicable accounting standards and the Hong Kong Listing Rules[109]. - The company has fully complied with the requirements for independent non-executive directors as per the Hong Kong Listing Rules during the reporting period[113]. - The company believes that having the same person serve as both Chairman and CEO is beneficial for its current stage of development, despite the deviation from the corporate governance code[111]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ending June 30, 2024[114]. Environmental Responsibility - The company invested RMB 797,700 in environmental protection during the reporting period[115]. - The company has established an environmental protection mechanism and has not faced any administrative penalties related to environmental issues during the reporting period[115]. - The company has implemented measures for air pollution control, adhering to the Shanghai industrial waste gas emission standards[115]. - The company has established a comprehensive energy-saving and water-saving performance management system, setting specific targets for each department to enhance resource utilization and reduce waste[119]. Shareholder Information - The company plans to issue a total of 38 million restricted shares under the incentive plan, representing approximately 3.67% of the total shares issued as of June 30, 2024[88]. - The board proposed an interim dividend of RMB 0.02 per share for the six months ending June 30, 2024, totaling RMB 20,731,442 based on 1,036,572,100 shares issued[69]. - The interim dividend distribution for A shares is approximately RMB 14,211,224, while for H shares it is about RMB 6,520,000[69]. - The company distributed dividends of RMB 0.05 and RMB 0.07 per share for the fiscal years ending December 31, 2020, and December 31, 2022, respectively[90].